查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球肿瘤影像人工智慧策略趋势（2025-2032）—路径、基础技术与实用指南
市场调查报告书
商品编码
1891236

全球肿瘤影像人工智慧策略趋势（2025-2032）—路径、基础技术与实用指南

Global Oncology Imaging AI Strategy Pulse 2025-2032: Pathways, Platforms and Playbooks
出版日期: | 出版商: Marketstrat, Inc. | 英文 102 Pages | 订单完成后即时交付

价格

摘要

预计全球癌症诊断领域的医学影像人工智慧市场规模将从2023年的6.047亿美元成长到2032年的77.4亿美元，复合年增长率（CAGR）为32.7%。 这将成为影像人工智慧领域成长最快的市场之一。

"全球肿瘤影像人工智慧策略趋势（2025-2032）—路径、基础技术和实用指南" 是Marketstrat发布的一份全球深度分析报告，揭示了医疗系统、原始设备製造商（OEM）和製药公司如何采购、实施和扩展癌症影像人工智慧。

本报告将肿瘤学定位为医学影像人工智慧的标竿应用案例。企业买家在此领域制定预算、治理规则、平台选择和证据标准，这将对所有其他人工智慧成像领域产生连锁反应。

本报告基于 Marketstrat 的 Markintel™ 框架，整合了以下内容：

  • 2023 年至 2032 年全球肿瘤影像人工智慧市场预测
  • 六大供应商集群的竞争格局（人工智慧软体、原始设备製造商、放射肿瘤学、平台、供应商/远端放射学以及诊断影像製药/合约研究组织）
  • 利用专有矩阵（M3、ARC、GTM 成长-成熟度、升级和包装阶梯）的实用上市 (GTM) 和包装策略手册

本报告提供策略层面的视角，旨在为影像人工智慧、肿瘤 IT、放射学、放射治疗、製药、私募股权和医疗系统领域的管理人员提供超越总资产管理 (TAM) 数据的更深入分析。本报告将为贵组织提供策略基础，帮助其确定在肿瘤影像人工智慧领域（截至 2032 年）的进入方向、建立竞争优势以及产品包装策略。

主要市场趋势

1. 从单一功能电脑辅助诊断 (CAD) 到以测量为中心、以路径为导向的人工智慧

  • 支出​​正从独立的检测应用转向以测量为中心的工作流程，例如分割、体积测量、RECIST/PERCIST 工具、放射组学、PET 剂量测定和结构化报告。
  • 虽然检测和诊断仍然是基础，但随着肿瘤委员会和支付方要求可重复的指标，而不仅仅是“人工智慧标记”，量化和分析以及报告和沟通变得越来越重要。

2.筛检项目作为永续人工智慧预算的基础

  • 美国、欧洲、中国、日本以及一些中等收入国家的国家和地区乳房数位乳房影像 (DBT) 和低剂量 CT (LDCT) 肺癌筛检计画已将人工智慧 (AI) 整合到其营运模式中（分流、二次阅片、品质保证、集中阅片）。
  • 供应商正日益将肿瘤人工智慧定位为筛检和放射治疗项目预算中的独立项目，而不是实验性的 IT 支出。

3. 治疗诊断与放射治疗计划作为高价值细分市场

  • PSMA/SSTR 治疗诊断 和先进的 PET/CT，结合自动勾勒和自适应放射治疗，将创造对多时相定量人工智慧的需求。
  • 肿瘤影像人工智慧将成为驱动治疗计划、疗效追踪以及最终基于价值的肿瘤学模型的测量引擎。

4. 平台化、市场与治理

  • 与PACS整合的AI市场、中立的AI平台和云端编排器消除了采用障碍，并支援在单一合约下使用多供应商的肿瘤解决方案。
  • 证据、验证和监控能力（AIops）正成为明确的招标标准，而不仅仅是 "锦上添花" 。

5. 亚太地区的强劲动能与全球差距

  • 亚太地区的成长速度目前已超越欧洲，这主要得益于政府主导的筛检和本土OEM厂商/平台的发展。
  • 与此同时，儘管拉丁美洲 (LATAM) 和中东及非洲 (MEA) 地区的普及程度仍然不均衡，但云端优先、以患者为中心的定价模式以及远距放射学模式的采用正在帮助缩小医疗服务获取差距。

6. 监理速度作为竞争优势

  • 在肿瘤领域，那些能够稳定获得 FDA、CE/MDR 和区域性批准的供应商正在赢得更多的商业竞标和由支付方主导的试点计画。
  • Marketstrat 的 ARC 指数（批准、报销、临床验证）依用例和集群量化了这一差距。

竞争格局

本报告将肿瘤影像人工智慧的竞争格局划分为六个清晰定义的集群，并分析每个集群的经济性、底层技术和市场进入策略：

人工智慧软体供应商

  • 乳房数位乳房断层合成（DBT）、肺部CT、PET反应分析、放射组学和肿瘤委员会报告。
  • 主要驱动因素：乳房DBT套件、肺部CT分流与管理。

影像设备製造商（CT/MR/PET/DBT/US）

  • 肿瘤套装的工厂配套和改装配件（DBT+AI、肺部CT、PET定量、重建/剂量AI、PCCT肿瘤）。
  • 控制硬体安装率和扫描器级捆绑销售。

放射治疗与肿瘤治疗计画供应商

  • 自动勾勒轮廓、计画品质保证、自适应放射治疗、反应关联计画和剂量累积。
  • 与治疗计画系统/​​直线加速器深度集成，在治疗室层面创造价值。

人工智慧平台和云端供应商

  • 中立的市场、编排层和受监管的人工智慧营运平台，支援透过单一合约进行部署和监控。

医疗机构与远距放射学网络

  • 人工智慧辅助筛检、肿瘤诊断判读、肿瘤委员会支持和网路品质保证。将应用层面的价值转化为服务线收入和成果。

影像製药/CRO/临床试验专业人员

  • 放射组学和定量终点、治疗诊断定量、病灶水平反应分析、真实世界数据 (RWE) 和健康技术评估 (HTA) 支持。

本报告在每个集群中提供：

  • Markintel M3（市场动量矩阵）-将细分市场分成四个像限。
  • GTM 成长成熟度矩阵 -依集群可视化公司市场地位。
  • 竞赛资料集与记分板 -供应商角色、通路、证据基础与地理优势。

这使策略制定者能够清楚地了解在哪些方面应该寻求合作、竞争、收购或内部开发。

本报告的意义

1. 专为策略制定而生，而非仅是市场规模估算

许多人工智慧市场报告都以 "总市场规模 (TAM)" 的问题结尾。本报告旨在为肿瘤影像人工智慧领域的董事会、高阶主管和业务部门决策提供支援。将价值直接与以下内容连结：

  • 产品组合选择（优先模式、肿瘤部位和治疗路径阶段）
  • 平台和合作策略（OEM、放射治疗、平台、供应商、製药）
  • 与证据和准备情况相符的定价、包装和升级结构

2.明确注意治疗路径与应用率

肿瘤人工智慧影像的成长并非由扫描仪数量的增加所驱动，而是由应用率的提高和临床流程的采用（筛检、放射治疗、诊疗一体化和治疗反应监测）所驱动。该模型透过以下要素清晰地重建了收入：

  • 依模式和国家划分的安装基数和检查量
  • 癌症人工智慧模组的工厂安装率和改造安装率
  • 依收入来源和最终用途划分的平均售价/每位用户平均收入区间

这使得预测对依赖应用率计算的原始设备製造商 (OEM)、软体供应商和平台更有用，而不仅仅是首席资讯长 (CIO) 的仪錶板。

3.市场进入策略 (GTM) 和产品包装的实用架构

Markintel 的框架堆迭将资料转换为具体、可验证的策略：

  • M3 市场动能矩阵
  • ARC 指数 清楚辨识已准备部署和处于试点阶段的用例。
  • GTM 成长成熟度 矩阵以集群识别合作伙伴、併购目标和竞争对手。
  • 升级和包装阶梯 展示如何将肿瘤人工智慧打包成基础型、高级型和精英型产品，并内建商业规则。

这尤其适用于：

  • 产品和组合负责人 - 决定投资、退出和打包哪些产品。
  • 市场推广、商业和定价团队 - 定义 SKU、底价和折扣结构。
  • 投资者和业务拓展/併购专业人士 - 识别具有结构性成长动能的平台和集群。

4. 基于证据的分析与供应商中立性

此分析以证据为依据，不带任何炒作，涵盖各地区的成熟企业和新兴企业。它提供：

  • 对各集群中的领先供应商现有和新兴供应商进行中立、系统化的分析。
  • 清晰展示排名和 ARC 评分的 "证据置信度" 。
  • 研究方法可根据新资料、试验和审批的出现进行完善和扩展。

5. 可重复使用

表格、图表和框架旨在以最小的修改直接整合到内部文件、投资委员会和业务发展备忘录以及董事会材料中，从而帮助团队：

  • 向非技术利害关係人解释复杂的肿瘤人工智慧趋势。
  • 基于量化、细分的证据来论证预算和策略投资的合理性。
  • 使产品、销售和合作伙伴关係路线图与对市场的共同理解保持一致。

公司列表：

  • 5C Network
  • Accuray
  • Aidoc
  • AIQ Solutions
  • Bracco
  • Brainlab
  • Canon Medical
  • CARPL.ai
  • deepc (deepcOS)
  • DocPanel
  • Elekta
  • Everlight Radiology
  • Ferrum Health
  • Fujifilm Healthcare
  • GE Health Care
  • Guerbet
  • Hologic
  • Incepto
  • Koios Medical
  • Lantheus/EXINI (aPROMISE/PYLARIFY AI)
  • Limbus AI
  • Lunit
  • Median Technologies
  • MIM Software
  • Mirada Medical
  • MVision AI
  • Nuance Precision Imaging Network (PIN)
  • Philips Healthcare
  • Quib​​im
  • QView Medical
  • RadNet/DeepHealth
  • RaySearch Laboratories
  • Riverain Technologies
  • Samsung Healthcare
  • ScreenPoint Medical (Transpara)
  • Siemens Healthineers
  • Teleradiology Solutions
  • Tempus (Arterys)
  • Therapixel （MammoScreen）
  • Unilabs/远距医疗诊所 (TMC)
  • 联影医疗
  • Vara
  • vRad

这份名单均衡涵盖了人工智慧软体专家、影像设备原始设备製造商 (OEM)、放射治疗设备/治疗计画系统供应商、平台营运商、医疗机构/远距放射学网路以及专注于肿瘤分析的影像相关製药公司/独立合约研究组织 (iCRO)。

目录

第一部分 - 如何利用此策略趋势

  • 本次报告解答的问题
  • 此策略趋势与地平线研究计画的关联
  • 哪些人应该使用本次报告以及原因？
  • 本文檔未涵盖的内容
  • 如何阅读文件其余部分

第二部分 - 摘要整理

  • 为何此市场至关重要 - 25 秒速览
  • 全球经济成长概况 (2023-2032)
  • 资金流向何方？
  • 全球市场驱动因素与限制因素
  • 区域脉搏 - 谁会引领，谁会加速？
    • 北美
    • 亚太地区
    • 欧洲
    • 拉丁美洲、中东和非洲
  • 重要证据与政策讯号（2025-2027）
  • 五大战略要点
  • 依模式、应用、途径和最终用途划分的结构性变化
  • 竞争架构与供应商集群
  • 三年关键绩效指标展望（2025-2027）与董事会层级行动
    • 三年关键绩效指标展望
    • 未来12个月的供应商举措

第三部分 - 研究方法

第四部分 - 策略分析与架构

  • 跨集群策略手册（2025-2027）
  • 人工智慧软体集群
    • 摘要整理
    • Markintel M3 - 市场动能矩阵（主要人工智慧软体细分市场）
    • Markintel ARC 框架 - 以人工智慧软体视角解决肿瘤应用案例
    • Markintel ARC 网格 - 人工智慧软体（肿瘤影像人工智慧）
    • Markintel GTM 成长成熟度矩阵 - 人工智慧软体供应商（肿瘤影像人工智慧）
    • Markintel 升级与软体套件阶梯 - 人工智慧软体（肿瘤影像人工智慧）
    • 公司聚焦 - 人工智慧软体集群
      • Aidoc
      • AIQ Solutions
      • Koios Medical
      • Lunit
      • Median Technologies
      • Quib​​im
      • QView Medical
      • RadNet/DeepHealth
      • Riverain技术
      • ScreenPoint Medical (Transpara)
      • Therapixel (MammoScreen)
      • Vara
    • 影像OEM群聚（肿瘤附属器及AI套件）
      • 摘要整理
      • Markintel M3 - 市场动能矩阵（主要影像OEM细分市场）
      • Markintel ARC框架 - OEM厂商解决的肿瘤影像AI用例
      • Markintel GTM成长成熟度矩阵 - 影像OEM（肿瘤影像AI）
      • 升级与封装阶梯 - 影像OEM镜头（肿瘤影像AI）
      • 寻找参与者 - 影像OEM（肿瘤附件及AI套件）
        • 佳能医疗
        • 富士软片医疗
        • GE医疗
        • Hologic
        • 飞利浦医疗保健
        • 三星医疗
        • 西门子医疗
        • 联影医疗
    • 放射治疗/肿瘤规划群聚（自动勾勒、自适应、剂量/反应）
      • 摘要整理
      • Markintel M3 - 关键细分市场市场动能矩阵（放射治疗/肿瘤规划视角）
      • Markintel ARC框架肿瘤应用案例（放射治疗/肿瘤规划视角）
      • Markintel GTM成长成熟度矩阵 - 放射治疗与肿瘤规划供应商（肿瘤影像AI）
      • Markintel升级与产品阶梯 - 放射治疗/肿瘤规划
      • 公司聚焦 - 放射治疗/肿瘤规划
        • Accuray
        • Brainlab
        • Elekta
        • Limbus AI
        • MIM软体
        • Mirada Medical
        • MVision AI
        • RaySearch Laboratories
        • Varian (Siemens)
    • AI 平台与云端集群（中立平台、编排、市场）
      • 摘要整理
      • Markintel M3 - 市场动能矩阵（AI 平台和云端的主要细分市场）
      • Markintel ARC 框架 - AI 平台和云端解决的肿瘤应用案例
      • 升级和软体包阶梯 - AI 平台和云端（肿瘤）
      • 公司聚焦 - AI 平台和云
        • CARPL.ai
        • deepc (deepcOS)
        • Ferrum Health
        • Incepto
        • Nuance 精准成像网路 (PIN)
        • Tempus （动脉）
    • 医疗服务提供者和远距放射学集群（人工智慧辅助服务）
      • 摘要整理
      • Markintel M3 市场动能矩阵（医疗服务提供者和远距放射学的关键细分市场）
      • Markintel ARC 框架 - 医疗服务提供者和远距放射学可触及的肿瘤应用案例
      • 上市成长成熟度矩阵 - 医疗服务提供者和远距放射学网路（肿瘤影像人工智慧）
      • Markintel 升级和套餐阶梯 - 医疗服务提供者和远距放射学（肿瘤）
      • 特色公司 - 医疗服务提供者和远距放射学（人工智慧辅助服务）
        • 5C Network
        • Everlight Radiology
        • DocPanel
        • RadNet/DeepHealth
        • 远距放射学解决方案
        • Unilabs/远距医疗诊所(TMC)
        • vRad
    • 影像製药/CRO 和临床试验集群（放射组学、反应、诊疗一体化）
      • 摘要整理
      • Markintel M3 市场动能矩阵（影像 - 製药/CRO 和临床试验的关键细分领域）
      • Markintel ARC 框架所涵盖的肿瘤影像 AI 应用案例 - 影像 - 製药/CRO 和临床试验
      • Markintel GTM 成长成熟度矩阵 - 影像製药和 CRO（肿瘤影像 AI）
      • 升级和打包阶梯 - 影像製药/CRO 和临床试验
      • 特色公司 - 影像製药/CRO 和临床试验（放射组学、反应、治疗诊断）
        • AIQ 解决方案
        • 布拉科
        • 格伯特
        • Lantheus/EXINI（aPROMISE/PYLARIFY AI）
        • 中位数技术 〈li>奎宾
Product Code: MINTP-M01119-1

Summary

The global oncology segment of medical imaging AI grows from US$ 604.7M in 2023 to US$ 7.74B in 2032, a 32.7% CAGR, making it one of the fastest-expanding pools in imaging AI.

"Oncology Imaging AI Strategy Pulse 2025-2032: Pathways, Platforms & Playbooks" is Marketstrat's global deep-dive on how cancer imaging AI is actually being bought, deployed, and scaled across health systems, OEMs, and pharma.

The report positions oncology as the reference use case for medical imaging AI-where enterprise buyers are defining budgets, governance rules, platform choices, and evidence standards that will spill over into every other AI-imaging domain.

Built on Marketstrat's Markintel(TM) framework stack, the report combines:

  • A 2023-2032 global market forecast for oncology imaging AI
  • Competitive architecture across six vendor clusters (AI software, OEMs, RT, platforms, providers/telerad, imaging pharma/CRO)
  • Actionable GTM and packaging playbooks using proprietary matrices (M3, ARC, GTM Growth-Maturity, Upgrade & Package Ladders)

The result is a strategy-grade view designed for executives in imaging AI, oncology IT, radiology, RT, pharma, private equity, and health systems who need more than high-level TAM numbers. If your organization is deciding where to play, how to win, and how to package in oncology imaging AI between now and 2032, this report is designed to be the strategic baseline you build on.

Key Market Trends

1. From single-use CAD to pathway-centric, measurement-first AI

  • Spend is shifting from isolated detection apps to measurement-centric workflows: segmentation, volumetrics, RECIST/PERCIST tools, radiomics, PET dosimetry, and structured reporting.
  • Detection & diagnosis remains foundational, but Quantification & Analytics and Reporting & Communication gain share as tumor boards and payers demand reproducible metrics, not just "AI flags."

2. Screening programs as durable AI budget anchors

  • National and regional breast DBT and LDCT lung screening initiatives in the US, Europe, China, Japan, and selected middle income markets are embedding AI into operating models (triage, second reads, QA, centralized reading).
  • For vendors, oncology AI increasingly shows up as a line item in screening and RT program budgets, rather than experimental IT spend.

3. Theranostics & RT planning as high-value niches

  • PSMA/SSTR theranostics and advanced PET/CT, combined with auto-contour and adaptive RT, create demand for multi timepoint quantitative AI.
  • Oncology imaging AI becomes the measurement engine behind treatment planning, response tracking, and eventual value based oncology models.

4. Platformization, marketplaces, and governance

  • PACS-integrated AI marketplaces, neutral AI platforms, and cloud orchestrators remove deployment friction and enable multi-vendor oncology suites under a single contract.
  • Evidence, validation, and monitoring capabilities (AIops) are becoming explicit RFP criteria, not a nice to have.

5. APAC momentum and global equity gaps

  • APAC's growth rate now exceeds Europe's, driven by state-backed screening and domestic OEMs/platforms.
  • At the same time, adoption remains uneven in LATAM and MEA, where cloud-first, PPU and teleradiology models are emerging to bridge access gaps.

6. Regulatory velocity as a competitive moat

  • Vendors with a steady cadence of oncology-relevant FDA, CE/MDR, and local approvals are winning more enterprise tenders and payer pilots.
  • Marketstrat's ARC-Index (Approvals, Reimbursement, Clinical validation) quantifies this gap by use case and cluster.

Competitive Landscape

The report maps the oncology imaging AI landscape into six tightly defined clusters, each with its own economics, rails, and GTM logic:

AI Software Vendors

  • Breast DBT, CT-lung, PET response analytics, radiomics, tumor-board reporting.
  • Prime Drivers: breast DBT suites, CT-lung triage & management.

Imaging OEMs (CT/MR/PET/DBT/US)

  • Factory and retrofit attach on oncology packs (DBT+AI, CT-lung, PET quant, recon/dose AI, PCCT oncology).
  • Control hardware attach-rate and scanner-level bundling.

RT & Oncology Planning Vendors

  • Autocontour, Plan QA, Adaptive RT, response-linked planning, dose accumulation.
  • Value realized at per-room level with tight TPS/linac integration.

AI Platforms & Cloud Providers

  • Neutral marketplaces, orchestration layers, governed AIops platforms delivering one-contract deployment and monitoring.

Providers & Teleradiology Networks

  • AI-assisted screening, oncology reads, tumor-board support, and network QA; convert app level value into service line revenue and outcomes.

Imaging Pharma / CRO & Trials Players

  • Radiomics and quantitative endpoints, theranostics quant, lesion-level response analytics, RWE and HTA support.

Within each cluster, the report provides:

  • Markintel M3 (Market Momentum Matrix) - showing segments in four quadrants
  • GTM Growth-Maturity Matrices - showing market position of companies by cluster.
  • Competitive Datasets & Scoreboards - vendor roles, channels, evidence posture, regions of strength.

This gives strategists a clear view of where to partner, where to compete, and where to buy or build.

Why This Report

1. Built for strategy, not just market sizing

Most AI market reports stop at "how big is the TAM." This report is designed for board, C suite, and BU level decisions in oncology imaging AI. It links numbers directly to:

  • Portfolio choices (which modalities, tumor sites, and pathway stages to prioritize)
  • Platform and partnership strategy (OEMs, RT, platforms, providers, pharma)
  • Pricing, packaging, and upgrade ladders aligned to evidence and readiness

2. Explicitly pathway and attach rate driven

Oncology imaging AI uplifts do not come from scanner unit growth-they come from attach rate expansion and pathway adoption (screening, RT, theranostics, response monitoring). The model explicitly reconstructs revenue via:

  • Installed base and exam volumes by modality and country
  • Factory and retrofit attach-rates for oncology AI modules
  • ASP/ARPU bands by revenue stream and end use

This makes the forecasts more useful for OEMs, software vendors, and platforms that live in attach rate math-not just high level CIO dashboards.

3. Actionable frameworks for GTM and packaging

The Markintel framework stack turns data into concrete, testable plays:

  • M3 Market Momentum Matrix
  • ARC-Index tells you which use cases are deployment-ready vs pilot stage.
  • GTM Growth-Maturity matrices identify partners, M&A targets, and competitors by cluster.
  • Upgrade & Package Ladders show how to package oncology AI into Foundation / Advanced / Elite offerings with embedded commercial rules.

This is particularly valuable for:

  • Product & portfolio leaders - deciding where to invest, sunset, or bundle.
  • GTM, commercial, and pricing teams - defining SKUs, floors, and discount structures.
  • Investors and BD/M&A - identifying platforms and clusters with structural momentum.

4. Evidence-weighted and vendor agnostic

The analysis is evidence-weighted, not hype-led, and spans both incumbents and challengers across regions. It provides:

  • Neutral, structured coverage of leading and emerging vendors in each cluster.
  • Clearly labeled Evidence Confidence levels for placements and ARC scores.
  • A methodology that can be revisited and extended as new data, trials, and approvals come online.

5. Designed to be reused

Tables, charts, and frameworks are crafted so they can be dropped directly into internal decks, investment committees, BD memos, and board packs with minimal rework, helping teams:

  • Explain complex oncology AI dynamics to non technical stakeholders.
  • Justify budgets and strategic bets with quantified, segmented evidence.
  • Align product, sales, and partnership roadmaps around the same view of the market.

Companies Mentioned:

  • 5C Network
  • Accuray
  • Aidoc
  • AIQ Solutions
  • Bracco
  • Brainlab
  • Canon Medical
  • CARPL.ai
  • deepc (deepcOS)
  • DocPanel
  • Elekta
  • Everlight Radiology
  • Ferrum Health
  • Fujifilm Healthcare
  • GE HealthCare
  • Guerbet
  • Hologic
  • Incepto
  • Koios Medical
  • Lantheus / EXINI (aPROMISE / PYLARIFY AI)
  • Limbus AI
  • Lunit
  • Median Technologies
  • MIM Software
  • Mirada Medical
  • MVision AI
  • Nuance Precision Imaging Network (PIN)
  • Philips Healthcare
  • Quibim
  • QView Medical
  • RadNet / DeepHealth
  • RaySearch Laboratories
  • Riverain Technologies
  • Samsung Healthcare
  • ScreenPoint Medical (Transpara)
  • Siemens Healthineers
  • Teleradiology Solutions
  • Tempus (Arterys)
  • Therapixel (MammoScreen)
  • Unilabs / Telemedicine Clinic (TMC)
  • United Imaging
  • Vara
  • vRad

The list is cluster balanced-it includes AI software specialists, modality OEMs, RT/TPS vendors, platform players, provider/telerad networks, and imaging pharma/iCROs that feature in the oncology analysis.

TABLE OF CONTENTS

SECTION 1 - HOW TO USE THIS STRATEGY PULSE

  • What This Pulse Answers
  • How This Strategy Pulse Relates to The Horizon Research Program
  • Who Should Use This Pulse-And for What
  • What Is Not in Scope
  • How To Read the Rest of the Document

SECTION 2 - EXECUTIVE SUMMARY

  • Why This Market Matters - The 25-Second Read
  • Global Growth at A Glance (2023-2032)
  • Where Along the Pathway the Money Is Moving
  • Global Market Drivers & Restraints
    • Key Growth Drivers
    • Structural Restraints
  • Regional Pulse - Who Leads, Who Accelerates
    • North America
    • Asia-Pacific
    • Europe
    • LATAM & MEA
  • Evidence & Policy Signals to Watch (2025-2027)
  • Five Strategy Headlines to Internalize
  • Structural Shifts by Modality, Application, Pathway, And End-Use
  • Competitive Architecture and Vendor Clusters
  • Three-Year KPI Outlook (2025-2027) & Board-Level Actions
    • Three-Year KPI Outlook
    • Actions For Vendors Over the Next 12 Months

SECTION 3 - RESEARCH METHODOLOGY

  • About This Strategy Pulse
  • Scope & Segmentation
  • Evidence & Forecast Architecture - Dual-Lens Build
  • Framework Stack & Vendor Clustering
  • Evidence Confidence, Limitations & Interpretation

SECTION 4 - STRATEGIC ANALYSIS & FRAMEWORKS

  • CROSS-CLUSTER STRATEGY PLAYBOOKS (2025-2027)
  • AI SOFTWARE CLUSTER
    • Executive Summary
    • Markintel M3 - Market Momentum Matrix (AI Software Key Sub-Segments)
      • How to Read This Matrix
    • Markintel ARC Framework - Oncology Use Cases Addressable by AI Software Lens
      • Markintel ARC Grid - AI Software (Oncology Imaging AI)
      • How to Read This Exhibit
      • ARC-Index by Segment - AI Software (Oncology Imaging AI)
      • ARC -> Upgrade Ladder Mapping - AI Software
      • Recommendations (AI Software Vendors)
    • Markintel GTM Growth-Maturity Matrix - AI Software Vendors (Oncology Imaging AI)
      • How To Read This Matrix
      • Competitive Dataset - AI Software - Oncology Imaging AI
      • Company Scoreboard - AI Software - Oncology Imaging AI
      • AI Software - Market Segmentation Bridge
    • Markintel Upgrade & Package Ladder - AI Software (Oncology Imaging AI)
      • Objective
      • Upgrade Ladder Structure - AI Software (Oncology) Packages
      • Target Customers & Package Composition - AI Software - Oncology Upgrade & Package Ladder42 Recommended Commercial Rules - AI Software (Oncology)
    • Company Spotlights - AI Software Cluster
      • Aidoc
      • AIQ Solutions
      • Koios Medical
      • Lunit
      • Median Technologies
      • Quibim
      • QView Medical
      • RadNet / DeepHealth
      • Riverain Technologies
      • ScreenPoint Medical (Transpara)
      • Therapixel (MammoScreen)
      • Vara
    • IMAGING OEMs CLUSTER (ONCOLOGY ATTACH & AI SUITES)
      • Executive Summary
      • Markintel M3 - Market Momentum Matrix (Imaging OEMs Key Sub-Segments)
        • How to Read This Matrix
      • Markintel ARC Framework - Oncology Imaging AI Use Cases Addressable by OEMs
        • Key OEM Oncology Segments
        • ARC Grid - Imaging OEMs
        • How to Read This Exhibit
        • ARC Table - Imaging OEMs (Oncology)
      • Markintel GTM Growth-Maturity Matrix - Imaging OEMs (Oncology Imaging AI)
        • Competitive Dataset - Imaging OEMS - Oncology Imaging AI
        • How to Read this Matrix
        • Imaging OEMs Competitive Scoreboard - Oncology Imaging AI
        • Imaging OEMs Cluster - Oncology Imaging AI Market Segmentation Bridge
      • Upgrade & Package Ladder - Imaging OEMs Lens (Oncology Imaging AI)
        • Objective
        • Ladder Structure - OEM Oncology Packages
        • Imaging OEMs - Oncology AI Upgrade & Package Ladder - Target Customers & Package Composition
        • Recommended Commercial Rules - OEM Oncology Cluster
      • Company Spotlights - Imaging OEMs (Oncology Attach & AI Suites)
        • Canon Medical
        • Fujifilm Healthcare
        • GE HealthCare
        • Hologic
        • Philips Healthcare
        • Samsung Healthcare
        • Siemens Healthineers
        • United Imaging
    • RT / ONCOLOGY PLANNING CLUSTER (AUTO-CONTOUR, ADAPTIVE, DOSE/RESPONSE)
      • Executive Summary
      • Markintel M3 - Market Momentum Matrix of Key Subsegments (RT/Oncology Planning Lens)
        • What it Says (RT / Oncology Planning)
      • Markintel ARC-Framework by Oncology Use Case (RT/Oncology Planning Lens)
        • ARC Grid - RT/Oncology Planning
        • ARC Table - RT / Oncology Planning
        • RT Recommendations
      • Markintel GTM Growth-Maturity Matrix -- RT & Oncology Planning Vendors (Oncology Imaging AI)
        • Competitor Scoreboard
        • RT / Oncology Planning - Market Segmentation Bridge
      • Markintel Upgrade & Package Ladder - RT / Oncology Planning
        • Objective
        • Ladder structure - RT / Oncology Planning packages
        • RT/Oncology Planning Cluster - Oncology AI Upgrade & Package Ladder - Target Customers & Package Composition
        • Recommended Commercial Rules - RT / Oncology Planning
      • Company Spotlights - RT / Oncology Planning
        • Accuray
        • Brainlab
        • Elekta
        • Limbus AI
        • MIM Software
        • Mirada Medical
        • MVision AI
        • RaySearch Laboratories
        • Varian (Siemens)
    • AI PLATFORMS & CLOUD CLUSTER (NEUTRAL PLATFORMS, ORCHESTRATION, MARKETPLACES)
      • Executive Summary
      • Markintel M3 - Market Momentum Matrix (AI Platforms & Cloud Key Sub-Segments)
        • What it Says (AI Platforms & Cloud)
      • Markintel ARC Framework - Oncology Use Cases Addressable by AI Platforms & Cloud
        • ARC Grid - AI Platforms & Cloud
        • ARC Table - AI Platforms & Cloud
        • Markintel GTM Growth-Maturity Matrix - AI Platforms & Cloud Providers (Oncology Imaging AI)74 Competitor Scoreboard
        • AI Platforms & Cloud - Market Segmentation Bridge
      • Upgrade & Package Ladder - AI Platforms & Cloud (Oncology)
        • Objective
        • Ladder Structure - Platform & Cloud packages
        • AI Platforms & Cloud - Oncology Upgrade & Package Ladder - Oncology Imaging AI
        • Recommended Default commercial Rules - Platforms & Cloud
      • Company Spotlights - AI Platforms & Cloud
        • CARPL.ai
        • deepc (deepcOS)
        • Ferrum Health
        • Incepto
        • Nuance Precision Imaging Network (PIN)
        • Tempus (Arterys)
    • PROVIDERS & TELERADIOLOGY CLUSTER (AI-ASSISTED SERVICES)
      • Executive Summary
      • Markintel M3 - Market Momentum Matrix (Providers & Teleradiology Key Subsegments)
        • What it Says (Providers & Telerad)
      • Markintel ARC Framework - Oncology Use Cases Addressable by Providers & Teleradiology
        • ARC Grid - Providers & Teleradiology
        • ARC Table - Providers & Teleradiology
      • GTM Growth-Maturity Matrix - Providers & Teleradiology Networks (Oncology Imaging AI)
        • Competitive Dataset - Services Rails, Governance, Oncology Footprint
        • Competitive Scoreboard
        • Providers & Teleradiology - Market Segmentation Bridge
      • Markintel Upgrade & Package Ladder - Providers & Teleradiology (Oncology)
        • Objective
        • Ladder Structure - Oncology Service Packages
        • Providers & Teleradiology - Oncology Upgrade & Package Ladder - Target Customers & Package Composition
        • Recommended Default Commercial Rules - Providers & Teleradiology
      • Company Spotlights - Providers & Teleradiology (AI-Assisted Services)
        • 5C Network
        • Everlight Radiology
        • DocPanel
        • RadNet / DeepHealth
        • Teleradiology Solutions
        • Unilabs / Telemedicine Clinic (TMC)
        • vRad
    • IMAGING-PHARMA / CRO & TRIALS CLUSTER (RADIOMICS, RESPONSE, THERANOSTICS)
      • Executive Summary
      • Markintel M3 - Market Momentum Matrix (Imaging-Pharma / CRO & Trials Key Sub-Segments)
        • M3 Table - Imaging-Pharma / CRO & Trials
      • Markintel ARC Framework - Oncology Imaging AI Use Cases Addressable by Imaging-Pharma / CRO & Trials
        • ARC Grid - Imaging-Pharma / CRO & Trials
        • ARC Table - Imaging-Pharma / CRO & Trials
      • Markintel GTM Growth-Maturity Matrix - Imaging-Pharma & CROs (Oncology Imaging AI)
        • Competitive Dataset - endpoint standardization & clinic bridge
        • Competitor Scoreboard
        • Imaging-Pharma / CRO & Trials - Market Segmentation Bridge
      • Upgrade & Package Ladder - Imaging-Pharma / CRO & Trials
        • Objective
        • Ladder Structure - Imaging-Pharma / CRO & Trials
        • Imaging-Pharma / CRO & Trials - Upgrade & Package Ladder - Target Customers and Package Composition
        • Recommended Default Commercial Rules - Imaging-Pharma / CRO & Trials
      • Company Spotlights - Imaging-Pharma / CRO & Trials (Radiomics, Response, Theranostics)
        • AIQ Solutions
        • Bracco
        • Guerbet
        • Lantheus / EXINI (aPROMISE / PYLARIFY AI)
        • Median Technologies
        • Quibim

List of Figures

  • Figure 1: World Oncology Imaging AI Market by Pathway Stage - 2023 vs 2032
  • Figure 2: Oncology Imaging AI - Global Drivers & Restraints
  • Figure 3: Oncology Imaging AI Market by Region - 2032 Revenue and 2023-2032 CAGR
  • Figure 4: Oncology Imaging AI Market by Modality - 2023 vs 2032
  • Figure 5: Oncology Imaging AI Market by Clinical Application - 2023 vs 2032
  • Figure 6: Oncology Imaging AI - Competitive Cluster Architecture
  • Figure 7: Markintel M3 - Market Momentum Matrix (AI Software Key Sub-Segments)
  • Figure 8: Markintel ARC Grid - AI Software - Oncology Imaging AI
  • Figure 9: Markintel GTM Growth vs. Maturity Matrix - AI Software Vendors (Oncology Imaging AI)
  • Figure 10: Upgrade & Package Ladder - AI Software - Oncology Imaging AI
  • Figure 11: Markintel M3 - Market Momentum Matrix (Imaging OEMs)
  • Figure 12: Markintel ARC Grid - Imaging OEMs - Oncology Imaging AI
  • Figure 13: Markintel GTM Growth vs. Maturity Matrix - Imaging OEM Vendors (Oncology Imaging AI)
  • Figure 14: Upgrade & Package Ladder - Imaging OEM Cluster - Oncology Imaging AI
  • Figure 15: Markintel M3 - Market Momentum Matrix - RT/Oncology Planning (Oncology Imaging AI) .
  • Figure 16: Markintel ARC Grid - RT/Oncology Planning - Oncology Imaging AI
  • Figure 17: Markintel GTM Growth vs. Maturity Matrix - RT/Oncology Planning (Oncology Imaging AI)
  • Figure 18: Upgrade & Package Ladder - RT/Oncology Planning Cluster - Oncology Imaging AI
  • Figure 19: Markintel M3 - Market Momentum Matrix (AI Platform & Cloud Sub-segment)
  • Figure 20: Markintel ARC Grid - AI Platforms & Cloud - Oncology Imaging AI
  • Figure 21: Markintel GTM Growth vs. Maturity Matrix - AI Platforms and Cloud (Oncology Imaging AI)
  • Figure 22: Upgrade & Package Ladder - AI Platforms & Cloud - Oncology Imaging AI
  • Figure 23: Markintel M3 - Market Momentum Matrix (AI Providers & Teleradiology Sub-Segment)
  • Figure 24: Markintel ARC Grid - Providers & Teleradiology - Oncology Imaging AI
  • Figure 25: Markintel GTM Growth vs. Maturity Matrix - Providers & Teleradiology (Oncology Imaging AI)
  • Figure 26: Upgrade & Package Ladder - Providers & Teleradiology Cluster - Oncology Imaging AI
  • Figure 27: Markintel M3 - Market Momentum Matrix (Imaging-Pharma/CRO & Trials Key Sub-Segment)
  • Figure 28: Markintel ARC Grid - Imaging-Pharma / CRO & Trials - Oncology Imaging AI
  • Figure 29: Markintel GTM Growth vs. Maturity Matrix - Imaging-Pharma / CRO & Trials (Oncology Imaging AI)
  • Figure 30: Upgrade & Package Ladder - Imaging-Pharma / CRO & Trials - Oncology Imaging AI